An otic suspension containing fianfloxacin (Xtoro) has approved by U.S Food and Drug Administration (FDA) to treat acute form of otitis externa.
Acute Otitis Externa:
Acute otitis externa is an infectious disease of ear that mainly target outer ear and ear canal. Acute otitis externa is also called as swimmer’s disease as this disease is mostly common among swimmers. Due to swimming the ear canal gets wet and risk of growth of microbes inside the ear amplify.
Sign and Symptoms of Acute Otitis Externa:
Some clinical features of acute otitis externa are as following;
- Inflammation of ear canal
- Pain in ear
- Discharge from ear.
Safety and Efficacy:
Finafloxacin belongs to flouroquinolone class of antibiotics is mainly effective against acute otitis exterana caused by Pseudomonas aeruginosa and S. aureus.
Xtoto was found to be safe and effective drug against swimmer’s disease by FDA after evaluating the results of two clinical trials in which 1,234 persons were enrolled.
Some common side effects that were observed during clinical trials are;
The current manufacture of Xtoto is Alcon Laboratories, Inc., based in Fort Worth, Texas.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.